Tarsus Pharmaceuticals (TARS)
(Delayed Data from NSDQ)
$32.04 USD
-0.17 (-0.53%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $32.00 -0.04 (-0.12%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
TARS 32.04 -0.17(-0.53%)
Will TARS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TARS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TARS
Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know
Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why
TARS: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91%
Here's Why Tarsus Pharmaceuticals, Inc. (TARS) is a Great Momentum Stock to Buy
Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last?
Other News for TARS
Commit To Buy Tarsus Pharmaceuticals At $15, Earn 7.6% Annualized Using Options
BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
Tarsus refinances existing debt with $200M financing commitment
Tarsus Pharmaceuticals Secures $75M Loan for Growth and Debt Repayment